Conditions: Early Parkinson's Disease
Keywords: SPM 962 rotigotine Parkinson's disease monotherapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 180
Healthy volunteers: no

Brief summary:
To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: SPM 962 intervention 2: placebo
Intervention descriptions: intervention 1: transdermal application, 1 time per day intervention 2: transdermal application, 1 time per day

Protocol document: